A Randomized Phase II Trial of Cisplatin With or Without Wee1 Kinase Inhibitor MK-1775 for First-line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (RM-SCCHN)

Trial Profile

A Randomized Phase II Trial of Cisplatin With or Without Wee1 Kinase Inhibitor MK-1775 for First-line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (RM-SCCHN)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 May 2017

At a glance

  • Drugs AZD-1775 (Primary) ; Cisplatin
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Aug 2016 Status changed from recruiting to discontinued.
    • 04 Aug 2016 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top